• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Callisto Pharmaceuticals, Inc. (CLSP) - Financial and Strategic SWOT Analysis Review Product Image

Callisto Pharmaceuticals, Inc. (CLSP) - Financial and Strategic SWOT Analysis Review

  • ID: 1315551
  • September 2011
  • 32 pages
  • GlobalData

FEATURED COMPANIES

  • ARYx Therapeutics, Inc.
  • MAP Pharmaceuticals, Inc.
  • Protalex, Inc.
  • MORE

Callisto Pharmaceuticals, Inc. (CLSP) - Financial and Strategic SWOT Analysis Review

Summary

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company engaged in the development of novel therapeutics for the treatment of neuroendocrine cancer, acute leukemia, rheumatoid arthritis and gastrointestinal disorders and diseases. The company’s pipeline products include Atiprimod, L-Annamycin and SP-304. In addition, Callisto also has a second generation guanylyl cyclase-C drug candidate SP-333 in the pre clinical stage of developemnt, used for the treatment of gastrointestinal inflammatory diseases and Plecanatide, a synthetic hexadecapeptide designed for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The company operates through two subsidiaries namely Synergy and Callisto Research Labs, LLC. It also provides contract pre- clinical development services in the field of Oncology. Callisto is headquartered in New York, the US.

This comprehensive SWOT profile of Callisto Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has READ MORE >

FEATURED COMPANIES

  • ARYx Therapeutics, Inc.
  • MAP Pharmaceuticals, Inc.
  • Protalex, Inc.
  • MORE



List of Tables
List of Figures
Section 1 - About the Company
Callisto Pharmaceuticals, Inc. - Key Facts
Callisto Pharmaceuticals, Inc. - Key Employees
Callisto Pharmaceuticals, Inc. - Key Employee Biographies
Callisto Pharmaceuticals, Inc. - Major Products and Services
Callisto Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
Callisto Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Callisto Pharmaceuticals, Inc., Pipeline Products by Development Phase
Callisto Pharmaceuticals, Inc. - History
Callisto Pharmaceuticals, Inc. - Company Statement
Callisto Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Callisto Pharmaceuticals, Inc. - Business Description
Callisto Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Callisto Pharmaceuticals, Inc. - Strengths
Strength - Atiprimod- Orphan Drug Status
Strength - Focused Research and Development Activities
Strength - Strong Intellectual Property Portfolio
Weakness - Limited Liquidity Position
Weakness - History of Operating Losses
Opportunity - Strategic Partnerships
Opportunity - Pipeline Products
Opportunity - Focus on Oncology
Threat - Intense Competition
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Uncertain R&D Outcomes
Callisto Pharmaceuticals, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Callisto Pharmaceuticals, Inc., Recent Deals Summary
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Callisto Pharmaceuticals, Inc., Key Facts
Callisto Pharmaceuticals, Inc., Key Employees
Callisto Pharmaceuticals, Inc., Key Employee Biographies
Callisto Pharmaceuticals, Inc., Major Products and Services
Callisto Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Callisto Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Callisto Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Callisto Pharmaceuticals, Inc., History
Callisto Pharmaceuticals, Inc., Subsidiaries
Callisto Pharmaceuticals, Inc., Key Competitors
Callisto Pharmaceuticals, Inc., Ratios based on current share price
Callisto Pharmaceuticals, Inc., Annual Ratios
Callisto Pharmaceuticals, Inc., Interim Ratios
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Callisto Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Callisto Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Callisto Pharmaceuticals, Inc., Pipeline Products by Development Phase
Callisto Pharmaceuticals, Inc., Performance Chart (2006 - 2010)
Callisto Pharmaceuticals, Inc., Ratio Charts
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Callisto Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

ARYx Therapeutics, Inc.
OncoVista Innovative Therapies, Inc.
Protalex, Inc.
Emergent Product Development Seattle LLC
Chelsea Therapeutics International Ltd.
MAP Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos